Drug Information Association Logo
« Back to Listing

Stage Gate Decision-Making Workshop (Part 1 of 2)

Track:
Project/Portfolio Management and Strategic Planning

Day & Time:
June 16, 8:30AM - 10:00AM (Pacific Standard Time)

Session Number:
104

Room Number:
16B

Level:
Basic

Type:
Workshop

Title:
Stage Gate Decision-Making Workshop (Part 1 of 2)

Chair(s):
Courtland R. LaVallee
Director, Project Management
Dynavax Technologies, United States

Description:
This interactive two-part workshop will help attendees who may be primarily involved in tactical activities understand how a company makes strategic decisions for moving a product forward. After a review of a new drug product, attendees will work in teams to discuss their product’s information and make recommendations for whether and how their product should be advanced through the development pipeline.

Workshop content is based on DIA's New Drug Product Development and Life Cycle Management training course. Part 1 of this workshop will focus on processes and decisions in phase 2, while Part 2 will focus on phase 3 and the decision to file.

Preregistration is required, and attendees are strongly encouraged to attend both Part 1 and Part 2.

Part 2 will take place on Monday at 11:00 am (Session #124).

To secure a seat for this specific workshop, please email annualmeetingprogram@diahome.org, Subject line: Stage Gate Decision-Making Workshop.

**Due to workshop format, seating will be limited.

The San Diego Convention Center has stringent regulations on maximum room capacities, and they are strictly enforced. Once all seats are occupied, DIA will be required to close the workshop, and no more participants will be admitted. Interested attendees are encouraged to arrive at workshops early in order to ensure seating. Please note, as a workshop with interactivity, this event will not be recorded.

Learning Objective(s):
Discuss the steps involved in determining whether a product should advance through the development pipeline; Describe the process and decisions made during phase 2.